Drug Profile
PF 6263276
Alternative Names: PF-06263276; PF-6263276Latest Information Update: 12 May 2015
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antipsoriatics
- Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 3 inhibitors; Janus kinase-2 inhibitors; TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Plaque psoriasis
Most Recent Events
- 27 Feb 2015 Discontinued - Phase-I for Plaque psoriasis (In volunteers) in Belgium (Topical)
- 27 Feb 2015 Discontinued - Phase-I for Plaque psoriasis in Germany (Topical)
- 01 Feb 2015 Pfizer completes a phase I trial in Plaque psoriasis in Germany (NCT02193815)